Touchlight unveils next-gen circular DNA portfolio for advanced gene therapies
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Subscribe To Our Newsletter & Stay Updated